How Itron’s Shift Toward Recurring Software and Resiliency Revenues May Influence Itron (ITRI) Investors

• In Q2 2026, Signia Capital Management added Itron, Inc. to its Small Cap Value portfolio, citing the utility-technology firm's progress in shifting from hardware to a recurring software and analytics model, supported by 22.1% year-over-year revenue growth in its Outcomes segment, which now accounts for 16% of total revenues.
• Itron's recent acquisitions of SaaS providers Urbint and Locusview further underline its move into higher-value Resiliency software, potentially reshaping how investors view the balance between its legacy hardware operations and its growing analytics-driven services.
• Now, we'll examine how Itron's push into recurring software revenues through Outcomes and Resiliency may influence its broader investment narrative.

The future of work is here. Discover the 39 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Itron Investment Narrative Recap

To own Itron, you need to believe utilities will keep investing in digital grid and water infrastructure, and that Itron can steadily mix more software and analytics into that spend. The recent Signia Capital move reinforces software progress, but does not change the near term reality that delayed utility projects and regulatory approvals remain a key swing factor for revenue timing and earnings volatility.

The Urbint and Locusview SaaS acquisitions are especially relevant here, because they expand Itron’s Resiliency and Outcomes offerings that generate recurring software and analytics revenues. As these platforms are integrated and commercialized, they sit alongside Itron’s recent contract wins and Q3 2026 revenue guidance as important proof points for whether the business can gradually rely less on large, hardware heavy deployments.

Yet, despite this shift toward higher value software, investors still need to be aware that prolonged regulatory or customer driven deployment delays could...

Read the full narrative on Itron (it's free!)

Itron's narrative projects $2.7 billion revenue and $313.0 million earnings by 2029. This requires 5.0% yearly revenue growth and a $24.0 million earnings increase from $289.0 million today.

Uncover how Itron's forecasts yield a $126.70 fair value, a 23% upside to its current price.

Exploring Other Perspectives

Four Simply Wall St Community fair value estimates span roughly US$71 to US$127, showing how far apart individual views on Itron can be. When you set those against Itron’s dependence on accelerating Outcomes and Resiliency software adoption, it becomes clear why many readers may want to compare several perspectives before forming expectations about the company’s future performance.

Explore 4 other fair value estimates on Itron - why the stock might be worth as much as 23% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Itron research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Itron research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Itron's overall financial health at a glance.

Want Some Alternatives?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 49 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com